Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-11-06

Clinical Trial Update: Spiriva® Assessment of FEV1 (SAFE) [Phase 3]

View source ↗

Summary

The Phase 3 SAFE trial evaluating Spiriva (tiotropium) for FEV1 assessment in chronic obstructive pulmonary disease has completed. The entry provides the trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Spiriva (tiotropium)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED